investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer

Fengzhi Li

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

Fengzhi Li

Roswell Park Cancer Institute

Buffalo, United States

Related projects

Monte Meier Winslow

Multiplexed in vivo drug screening: Inhibitors of metastatic seeding

Pancreas

Samuel Strober

Radiotherapy as Immunotherapy of Tumors

Pancreas

Radiation Oncology

Walter Gwang-Up Park

A Clinical Center to Study Immunological and Hormonal Biomarkers for the Diagnosis, Prediction and Treatment of Chronic Pancreatitis and its associated development to Diabetes and Pancreas Cancer

Pancreas

Pathology

Qizhi C. Yao

A novel miR-198 replacement therapy for pancreatic cancer

Pancreas

Pathology

Samuel I Gunderson

Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer

Pancreas

Paul A Scheet

Discovery of Risk Loci and Genomics of Pancreatic Cancer through Exome Sequencing

Pancreas

Vladimir Bogdanov

Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic Cancer

Pancreas

Pathology

Robert M Straubinger

Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium

Pancreas

Pathology

Udo Rudloff

Preclinical Drug Development in Pancreatic Cancer

Pancreas

Pathology